PreprintCase ReportVersion 1This version is not peer-reviewed
A Case Of Successful Dupilumab Treatment In Allergic Rhinitis And Atopic Dermatitis In Patient With Multiple Food Allergies, Pollen And Perennial Sensitization
Version 1
: Received: 31 October 2024 / Approved: 31 October 2024 / Online: 1 November 2024 (12:44:36 CET)
How to cite:
Sculco, E.; Garzi, G. A Case Of Successful Dupilumab Treatment In Allergic Rhinitis And Atopic Dermatitis In Patient With Multiple Food Allergies, Pollen And Perennial Sensitization. Preprints2024, 2024110012. https://doi.org/10.20944/preprints202411.0012.v1
Sculco, E.; Garzi, G. A Case Of Successful Dupilumab Treatment In Allergic Rhinitis And Atopic Dermatitis In Patient With Multiple Food Allergies, Pollen And Perennial Sensitization. Preprints 2024, 2024110012. https://doi.org/10.20944/preprints202411.0012.v1
Sculco, E.; Garzi, G. A Case Of Successful Dupilumab Treatment In Allergic Rhinitis And Atopic Dermatitis In Patient With Multiple Food Allergies, Pollen And Perennial Sensitization. Preprints2024, 2024110012. https://doi.org/10.20944/preprints202411.0012.v1
APA Style
Sculco, E., & Garzi, G. (2024). A Case Of Successful Dupilumab Treatment In Allergic Rhinitis And Atopic Dermatitis In Patient With Multiple Food Allergies, Pollen And Perennial Sensitization. Preprints. https://doi.org/10.20944/preprints202411.0012.v1
Chicago/Turabian Style
Sculco, E. and Giulia Garzi. 2024 "A Case Of Successful Dupilumab Treatment In Allergic Rhinitis And Atopic Dermatitis In Patient With Multiple Food Allergies, Pollen And Perennial Sensitization" Preprints. https://doi.org/10.20944/preprints202411.0012.v1
Abstract
Dupilumab is an interleukin 4 (IL-4) receptor α-antagonist that inhibits IL-4 and IL-13 signaling through blockade of the shared IL-4αR subunit. Blockade of IL-4/13 is effective in reducing Th2-oriented response including the release of proinflammatory cytokines, chemokines, and IgE. These mechanisms are known as mediators in the pathogenesis of atopic dermatitis, food allergy, allergic rhinitis with and without polyposis, and asthma. We report the clinical case of a patient in which the Th2-mediated inflammatory substrate is evident in comorbid allergic manifestations who show a good response after treatment with Dupilumab for moderate atopic dermatitis
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.